原发性睾丸弥漫大B细胞淋巴瘤的临床特征与预后分析
礼仕可1,2, 施文瑜2, 张卓3, 张锋3, 孙秀华31. 大连医科大学研究生院, 辽宁 大连 116044;
2. 南通大学附属医院肿瘤科, 江苏 南通 226001;
3. 大连医科大学附属第二医院肿瘤科, 辽宁 大连 116027
收稿日期:
2023-07-09出版日期:
2023-12-30发布日期:
2023-12-12通讯作者:
施文瑜E-mail:shiwenyu@hotmail.com作者简介:
礼仕可(1998-),女,硕士研究生基金资助:
吴阶平医学基金会临床科研专项资助基金(320.6750.2021-02-56)关键词: 原发性睾丸淋巴瘤, 弥漫大B细胞淋巴瘤, 临床特征, 预后
Abstract: Objective To investigate the clinical characteristics and prognosis of primary testicular diffuse large B-cell lymphoma (PT-DLBCL).Methods The clinical data, treatment regimen and prognosis of PT-DLBCL patients were analyzed retrospectively, from the records of the Affiliated Hospital of Nantong University and the Second Affiliated Hospital of Dalian Medical University from Jan. 1, 2000 to Dec. 31, 2022.Results The median age of the 47 PT-DLBCL patients was 64 years old. The median overall survival (OS) was 41.6 months, with 1-year, 3-year, and 5-year PT-DLBCL OS of 93%, 77%, and 59%, respectively. Kaplan-Meier univariate analysis demonstrated that a diagnosed age ≥ 70 years, Eastern cooperative oncology group (ECOG) score ≥ 3, international prognostic index (IPI) score ≥ 4, no combination of anthracycline and rituximab, a single treatment regimen, ineffective initial treatment and relapse, were associated with an adverse prognosis in PT-DLBCL (all P < 0.05). Multivariate Cox regression analysis showed that an ECOG score ≥ 3, no application of Rituximab, and an ineffective initial treatment response were independent risk factors for the poor prognosis of PT-DLBCL (all P < 0.05).Conclusion PT-DLBCL is rare and associated with a poor prognosis. Early diagnosis and therapy with a combination of anthracyclines and rituximab may improve outcomes.
Key words: primary testicular lymphoma, diffuse large B-cell lymphoma, clinical characteristics, prognosis
PDF全文下载地址:
https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3328